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In a previous paper, we reported that lipoteichoic acids
(LTA) prepared from Streptococcus pyogenes induces tumour
necrosis factor (TNF) in the sera of mice which had been
primed with formalin-killed Propionibacterium acnes
(Yamamoto et al., 1985a). Thus, serum specimens of P.
acnes-primed, and LTA-elicited mice had a cytoidal effect on
L-929 cells in vitro, and the i.v. injection of the sera caused
haemorrhagic necrosis in pre-established Meth A solid-type
tumours in BALB/c mice without any apparent undesirable
effects. In a succeeding study, we demonstrated that LTA
administered to mice inoculated with Meth A fibrosarcoma,
either ascites- or solid-type, caused a significant suppression
of tumour growth (Usami et al., 1988).
It is well known that endotoxic lipopolysaccharide (LPS)
inhibits tumour growth in experimental animals, and that it
is a potent inducer of TNF in various primed animals
(Nowotny, 1969; Carswell et al., 1975). However, LPS has
high endotoxicities, including lethal toxicity, which make it
almost impossible to use LPS as an antitumour agent in
clinical medicine. This paper presents evidence which
strongly suggests that LTA-induced TNF is distinct in
toxicity from that induced by LPS, although they share some
antigenic epitopes.
LTA was prepared as described previously (Yamamoto et
al., 1985a). The purity of the LTA preparation was assessed
by gas-liquid chromatography, and by chemical and
immunochemical analysis (Hamada et al., 1985). Chemical
analysis showed that the ratio among glycerol, fatty acids
and alanine found in the LTA was consistent with those
reported by Ofek et al. (1975). The Limulus lysate assay
indicated that mg of this LTA preparation contained
<280 pg of LPS.
The tumour necrosis factor was induced as follows:
Groups of CD-1 (female, 6 weeks old, Charles River Japan,
Atsugi, Japan) mice were primed by i.p. injection of 1.5mg
of formalin-killed P. acnes. Nine days later they were elicited
by i.v. injection of either 100/g of LTA, or 10 lg of
Salmonella abortus-equi LPS (a gift of Dr C. Galanos, Max-
Planck Institute for Immunology). Sera (containing LTA- or
LPS-induced TNF) obtained from the blood drawn 1.5h
after the elicitation were heated at 56°C for 30min to abolish
nonspecific cytotoxic activity against tumour cells. Sera
containing TNF were centrifuged at 100,000g for 60min,
and the supernatant was concentrated by ultrafiltration
through membrane PM1O (Amicon, Danv., MA., USA). The
concentrate was then fractionated by fast-protein liquid
chromatography (FPLC system, Pharmacia, Uppsala,
Sweden) equipped with a TSK 3,000SW column (Toyo Soda
Industries Ltd., Tokyo, Japan) which had been equilibrated
with 0.05 M potassium phosphate buffer containing 0.3 M
NaCI, pH6.9.
The fractions were eluted with the same buffer, and each
fraction was tested for TNF activity by the L-929 lytic assay
(Aggarwal et al., 1985). Active fractions were pooled and
concentrated by the ultrafiltration described above. The
LTA- and LPS-induced TNF thus obtained, were adjusted to
56,000 units of TNF activity per ml (Yamamoto et al.,
1986b). The Limulus assay showed that both LPS-induced
TNF and LTA-induced TNF were practically free of LPS.
No interferon activities were detected in either preparation.
Eleven mouse tumour cell lines were tested for suscepti-
bility to the growth-inhibiting effects of LTA- and LPS-
induced TNF (Table I). Cytostatic assays were performed as
described in a previous paper (Yamamoto et al., 1985b). The
growth of Meth A fibrosarcoma, C1498 myeloid leukaemia,
EL-4 lymphoma, L1210 leukaemia, P388 leukaemia, MH-134
hepatoma and 3LL lymphoma was significantly inhibited by
a 1:100 dilution of LTA-induced TNF. But there was no
significant inhibition of the growth of BAMC-1 fibro-
sarcoma, X5563 plasmacytoma, and B16 melanoma. Meth
A, 3LL and L-929 cells were more susceptible than others, as
evidenced by the fact that their growth was significantly
inhibited by a 1:1000 dilution of the LTA-induced TNF,
Table I Cytostatic effects of LTA- and LPS-induced TNF on
various mouse tumour cell lines
Cytostatic effect (%)a
LTA-induced TNF LPS-induced TNF
Cell line j/loob 1/1000 1/100 1/1000
Non-adherent cells
Meth A 66.5**c 43.7** 54.6*** 39.7**
C1498 54.2** 8.8 59.6** 11.8
EL-4 51.4** 9.8 71.3*** 56.9**
L1210 39.3** 2.7 28.0 9.0
P388 37.6** 6.7 27.7 6.8
MH-134 30.9* 6.5 54.0*** 14.5
BAMC-1 17.3 12.7 19.1 7.4
X5563 7.0 7.0 33.6 3.9
Adherent cells
3LL 73.2*** 54.8*** 60.7*** 34.9**
B16 20.7 5.6 39.6*** 10.0
L-929 97.8*** 94.5*** 97.4*** 96.7***
The diluted LTA- or LPS-induced TNF was added to 1 to 2 x 104
cells in 8% FCS-RPMI 1640 medium (200MI in total volume) and
the cells were cultured at 37'C for 48h in 5% C02-air. Each test
was made in triplicate. '(l - cpm in test/cpm in the respective
control) x 100%; 'TNF was diluted with RPMI 1640 medium
supplemented with 8% FCS; cSignificantly different from the control
(medium): ***P<0.001, **P<0.01, *P<0.1.
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which hardly affected other cell lines. The patterns of growth
inhibition by the LTA-induced TNF was very similar to that
by the LPS-induced TNF, although some differences were
noted in the cytostatic effects on L1210 leukaemia, P388
leukaemia and B16 melanoma.
Against human tumour cell lines, both the LTA- and LPS-
induced TNF showed cytocidal effects on BT-20 (a breast
tumour cell line) and ME-180 (a cervical tumour cell line),
but neither preparation affected the viability of WISH, a
normal cell line (data not shown). Thus the LTA- and LPS-
induced TNFs were similar in their mode ofcytotoxic action,
i.e., lack of species specificity and the ability to discriminate
between tumour cells and normal cells. The necrotizing effect
of LTA-induced TNF on solid-type Meth A fibrosarcoma
pre-established in BALB/c mice was described previously
(Yamamoto et al., 1985a).
The antigenic relationship between LTA- and LPS-induced
TNF was determined by a neutralization test using anti-TNF
serum obtained by immunizing rabbits with a highly purified
LPS-induced TNF which has a single protein band in SDS-
polyacrylamide gel electrophoresis (Haranaka et al., 1986).
Thus anti-mouse TNF almost completely neutralized the
cytotoxic activity in L-929 cells of both LTA- and LPS-
induced TNF (Table II). Normal rabbit serum had no effect
on either TNF in control. assays. This indicates that the
LTA-induced TNF is antigenically related to LPS-induced
TNF. It may also exclude the possibility that the LTA-
induced TNF contains lymphotoxin (LT) in an appreciable
amount, since Stone-Wolff et al. (1984) reported that LT
was antigenically different from TNF.
We reported previously that no death of P. acnes-primed
CD-1 mice was caused by LTA, even at a dose as high
i mg/mouse under assay conditions in which the LDo50 of
LPS was 3.13 ig/mouse (Yamamoto et al., 1985a). The
extreme low toxicity of LTA was further confirmed using
galactosamine-loaded mice which are known to be highly
susceptible to the lethal effects of toxic bacterial products.
LTA was found to be - 1.3 x 106 times less toxic than LPS
in galactosamine-loaded C3H/HeN mice and 7 x 104 times
less so in C57BL/6 mice (data not shown).
On the other hand, there are several reports that the LPS-
induced TNF (cachectin/TNF) is highly toxic to mice
(Cerami et al., 1985; Torti et al., 1985; Caput et al., 1986). A
recent study by Lehmann et al. (1987) demonstrated that the
recombinant TNF was lethally toxic not only to C3H/HeN
but also to LPS-nonresponding C3H/HeJ mice both of
which were loaded with galactosamine. In addition, Beutler
et al. (1985) reported that the LPS-induced TNF was one of
the principal mediators of the lethal effect of LPS. In view of
these studies, we determined whether or not the LTA-
induced TNF was toxic to galactosamine-loaded mice. As
shown in Table III, none of the galactosamine-loaded mice
employed in this study were killed by injections of LTA-
induced TNF. In contrast, the injection of the LPS-induced
TNF was highly lethal within one day in the C3H/HeJ mice
(non-LPS-responder, male, 9 weeks old, Jackson Lab., Bar
Harbor, USA) and in the C3H/HeN and C57BL/6 mice
(high and moderate LPS responders, respectively, male, 9
weeks old, Charles River Japan). This indicates that the
observed result was not due to the presence of LPS in the
specimen, but to the LPS-induced TNF itself. In this
connection, none of galactosamine-loaded C3H/HeJ mice
were killed by the injection of 500#g LPS, in accordance
Table II Neutralization of LTA-induced TNF by anti-TNF serum.
Cytotoxicity Neutralization
Factor Treated with (%) (%)
LTA-induced RPMI-1640 medium 82.3 0
TNF Anti-TNF serum 6.7 91.9*a
Normal serum 83.4 -1.0
LPS-induced RPMI-1640 medium 80.4 0
TNF Anti-TNF serum 14.4 82.0*
Normal serum 84.9 -5.5
The LTA- or LPS-induced TNF were incubated with anti-TNF
serum (see text) at 37°C for 1 h, and then TNF activity of the
mixture was determined by L-929 lytic assay. aSignificantly different
from the control (medium): *P<0.001.
Table III Comparison of lethal toxicity of LTA- and LPS-induced
TNF in galactosamine-loaded mice.
Dead mice/total mice
C3H/HeN C57BL/6 C3H/HeJ
TNFspecimen (high)a (moderate) (none or low)
LTA-induced TNF 0/5 0/5 0/5
LPS-induced TNF 5/5 5/5 5/5
The LTA- and LPS-induced TNF having the same level of TNF
activity (5,600 units) were injected i.v. into groups of C57BL/6,
C3H/HeN and C3H/HeJ mice (5 per group) with 16mg
galactosamine. The death of mice were observed for 7 days.
aSusceptibility to the lethal toxicity of LPS.
with the report of Freundenberg et al. (1986) (data not
shown). Thus the above finding clearly demonstrates that
LTA-induced TNF is definitely different from LPS-induced
TNF in its lethality against galactosamine-loaded mice.
Precisely why the LTA-induced TNF is far less toxic than
LPS-induced TNF is still unknown. However, one
explanation may be that LTA-induced TNF has no epitope
responsible for the lethal toxicity, although LTA- and LPS-
induced TNFs have a similar (or the same) epitope
associated with cytotoxicity. In any event, the results
presented here suggest that another type(s) of TNF can be
induced in P. acnes-primed mice by injection of LTA.
In summary, the LTA-induced TNF inhibited the growth
of a wide spectrum of tumour cell lines of both mouse and
human origin, and it discriminated between normal and
tumour cells in vitro, as did the LPS-induced TNF. The
LTA-induced TNF was far less toxic than the LPS-induced
TNF in galactosamine-loaded C3H/HeN, C3H/HeJ and
C57BL/6 mice under experimental conditions in which the
LPS-induced TNF was highly toxic. Thus it appears possible
that LTA can be used to induce nontoxic TNF. But further
purification and biochemical characterization of the LTA-
induced TNF are needed to establish its relationship to the
standard LPS-induced TNF.
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